Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642990 · ClinicalTrials.gov registry record · Phase 2
NR in Chemo-induced Peripheral Neuropathy
A Phase 2 study, sponsored by Donna Hammond, PhD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03642990 is a Phase 2 study that was terminated before completion, run by Donna Hammond, PhD. The registered enrollment target is 5 participants.
The verdict
NCT03642990, a Phase 2 study, was terminated before completion, sponsored by Donna Hammond, PhD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.
Interventions
- DRUG Nicotinamide Riboside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2022-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03642990
The ClinicalTrials.gov registry entry for NCT03642990 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Donna Hammond, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nicotinamide Riboside is the first listed.
NCT03642990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03642990 about?
NCT03642990 is a clinical study titled "NR in Chemo-induced Peripheral Neuropathy". The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistan...
What is the current status of trial NCT03642990?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-11-08. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03642990?
The interventions under investigation include: Nicotinamide Riboside (DRUG).
Who is sponsoring clinical trial NCT03642990?
This trial is sponsored by Donna Hammond, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.